MA66598A1 - Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux - Google Patents
Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreuxInfo
- Publication number
- MA66598A1 MA66598A1 MA66598A MA66598A MA66598A1 MA 66598 A1 MA66598 A1 MA 66598A1 MA 66598 A MA66598 A MA 66598A MA 66598 A MA66598 A MA 66598A MA 66598 A1 MA66598 A1 MA 66598A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- administration
- anticancer drug
- phthalazinone derivative
- phthalazinone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302834P | 2022-01-25 | 2022-01-25 | |
| PCT/IB2023/000030 WO2023144626A1 (en) | 2022-01-25 | 2023-01-25 | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA66598A1 true MA66598A1 (fr) | 2024-11-29 |
Family
ID=87470837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA66598A MA66598A1 (fr) | 2022-01-25 | 2023-01-25 | Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250120970A1 (https=) |
| EP (1) | EP4469051A4 (https=) |
| JP (1) | JP2025505381A (https=) |
| KR (1) | KR20240138069A (https=) |
| CN (1) | CN118613264A (https=) |
| AU (1) | AU2023210923A1 (https=) |
| CA (1) | CA3249330A1 (https=) |
| CL (1) | CL2024002218A1 (https=) |
| IL (1) | IL314334A (https=) |
| JO (1) | JOP20240162A1 (https=) |
| MA (1) | MA66598A1 (https=) |
| MX (1) | MX2024009168A (https=) |
| TW (1) | TW202339753A (https=) |
| WO (1) | WO2023144626A1 (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019426A1 (zh) * | 2010-08-09 | 2012-02-16 | 上海恒瑞医药有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| WO2015037939A1 (en) * | 2013-09-13 | 2015-03-19 | Ildong Pharm Co., Ltd. | A novel phtalazinone derivatives and manufacturing process thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2833883A4 (en) * | 2012-04-06 | 2015-12-23 | Indus Pharmaceuticals Inc | NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
| JP7626783B2 (ja) * | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| AU2020444056A1 (en) * | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
-
2023
- 2023-01-25 EP EP23746538.0A patent/EP4469051A4/en active Pending
- 2023-01-25 CN CN202380018679.4A patent/CN118613264A/zh active Pending
- 2023-01-25 KR KR1020247022669A patent/KR20240138069A/ko active Pending
- 2023-01-25 MA MA66598A patent/MA66598A1/fr unknown
- 2023-01-25 CA CA3249330A patent/CA3249330A1/en active Pending
- 2023-01-25 JP JP2024543458A patent/JP2025505381A/ja active Pending
- 2023-01-25 WO PCT/IB2023/000030 patent/WO2023144626A1/en not_active Ceased
- 2023-01-25 IL IL314334A patent/IL314334A/en unknown
- 2023-01-25 US US18/730,930 patent/US20250120970A1/en active Pending
- 2023-01-25 AU AU2023210923A patent/AU2023210923A1/en active Pending
- 2023-01-25 MX MX2024009168A patent/MX2024009168A/es unknown
- 2023-01-30 TW TW112103190A patent/TW202339753A/zh unknown
-
2024
- 2024-07-23 JO JOJO/P/2024/0162A patent/JOP20240162A1/ar unknown
- 2024-07-23 CL CL2024002218A patent/CL2024002218A1/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012019426A1 (zh) * | 2010-08-09 | 2012-02-16 | 上海恒瑞医药有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| WO2015037939A1 (en) * | 2013-09-13 | 2015-03-19 | Ildong Pharm Co., Ltd. | A novel phtalazinone derivatives and manufacturing process thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023144626A1 (en) | 2023-08-03 |
| JOP20240162A1 (ar) | 2024-07-23 |
| CN118613264A (zh) | 2024-09-06 |
| EP4469051A4 (en) | 2025-12-17 |
| MX2024009168A (es) | 2024-08-09 |
| IL314334A (en) | 2024-09-01 |
| EP4469051A1 (en) | 2024-12-04 |
| US20250120970A1 (en) | 2025-04-17 |
| JP2025505381A (ja) | 2025-02-26 |
| TW202339753A (zh) | 2023-10-16 |
| KR20240138069A (ko) | 2024-09-20 |
| CL2024002218A1 (es) | 2024-12-20 |
| AU2023210923A1 (en) | 2024-07-25 |
| CA3249330A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
| MA29744B1 (fr) | Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree | |
| Davidson et al. | Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo‐controlled, blinded experience in 2382 patients with primary hypercholesterolemia | |
| MA27154A1 (fr) | Derives de quinazoline pour le traitement d'une croissance cellulaire anormale | |
| MX2022003446A (es) | Composiciones de vesiculas lipidicas con agentes potenciadores de la penetracion. | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA27710A1 (fr) | Formulations pharmaceutiques liquides de palonosetrone | |
| MA34516B1 (fr) | Imidizopyridazines substituees | |
| CA2294783A1 (fr) | Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine | |
| MA29606B1 (fr) | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol | |
| MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
| MA26965A1 (fr) | Association d'agonistes de gaba et d'inhibiteurs d'aldose-reductase. | |
| MA52154B1 (fr) | Composition pharmaceutique pour l'anémie | |
| WO2001010387A3 (en) | Antiviral therapy use of P-glycoprotein modulators | |
| MA66598A1 (fr) | Composition pharmaceutique comprenant un dérivé de phtalazinone pour coadministration avec un médicament anticancéreux | |
| PT94832A (pt) | Processo para a preparacao de derivados substituidos de aminoalcoxibenzeno e de composicoes farmaceuticas que os contem | |
| FR3055801B1 (fr) | Derives esters de squalamine pour le traitement des infections | |
| CA3156022A1 (en) | METHODS OF TREATING CANCER USING A COMBINATION OF A PLATINUM AGENT AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE | |
| MA62917A1 (fr) | Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens | |
| CO2021005221A2 (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| FR3108504B1 (fr) | Phytoecdysones et leurs dérivés pour leur utilisation dans le traitement d’altérations de la fonction respiratoire lors d’une infection virale | |
| Paraskevas et al. | Contrast-induced nephropathy and the vascular patient | |
| BR112022026558A2 (pt) | Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo | |
| MX2007002941A (es) | Composiciones de emulsion estables para administracion intravenosa que tienen eficacia libre de conservadores. | |
| Bhogal et al. | Pharmacological treatment of social phobia |